CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Basu, A.
Right arrow Articles by Saijo, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Basu, A.
Right arrow Articles by Saijo, N.

Cell Growth & Differentiation, Vol 7, Issue 11 1507-1512, Copyright © 1996 by American Association of Cancer Research


ARTICLES

Characterization of the protein kinase C signal transduction pathway in cisplatin-sensitive and -resistant human small cell lung carcinoma cells

A Basu, K Weixel and N Saijo
Department of Pharmacology, University of Pittsburgh, Pennsylvania 15261, USA. anb@prophet.pharm.pitt.edu

Protein kinase C (PKC) influences cellular sensitivity to cis-diamminedichloroplatinum(II) (cDDP). We have investigated whether the PKC signal transduction pathway is affected during the development of cellular resistance to cDDP. Activators of PKC, such as phorbol 12,13-dibutyrate (PDBu), enhanced the sensitivity of human small cell lung cancer H69 cells to cDDP by 2-fold but had no effect on the sensitivity of cDDP-resistant H69 cells (H69/CP) to cDDP. The maximum sensitization was achieved with 10 nM PDBu and blocked by down-regulation of PKC with higher concentrations of PDBu (1 microM) or bryostatin 1 (0.1 microM). PKC activity was decreased significantly in H69/CP cells compared to the drug-sensitive variant. A similar reduction in PKC activity was noted in ovarian carcinoma 2008 cells that were resistant to cDDP. A modest decrease in PKC activity was also observed in etoposide-resistant H69 (H69/VP-16) cells but not in Taxol-resistant H69 cells or bleomycin-resistant human head and neck carcinoma A-253 cells. H69 cells expressed conventional PKC alpha and-beta, novel PKC delta, atypical PKC zeta and-iota, and novel/atypical PKC mu. A decrease in cPKC alpha and-beta and an increase in nPKC delta were associated with the cDDP-resistant phenotype. The abundance of aPKC zeta or-iota was unaffected. H69/ VP-16 cells also displayed a reduction in cPKC beta and an increase in nPKC delta. Taxol-resistant H69 cells had no alteration in the expression of any of the PKC isozymes. Thus, a reduction in cPKCs and an increase in nPKC may be associated with cDDP resistance.


This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
M. B. Abera and M. G. Kazanietz
Protein Kinase C{alpha} Mediates Erlotinib Resistance in Lung Cancer Cells
Mol. Pharmacol., May 1, 2015; 87(5): 832 - 841.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Amos, M. Mut, C. G. diPierro, J. E. Carpenter, A. Xiao, Z. A. Kohutek, G. T. Redpath, Y. Zhao, J. Wang, M. E. Shaffrey, et al.
Protein Kinase C-{alpha} Mediated Regulation of Low-Density Lipoprotein Receptor Related Protein and Urokinase Increases Astrocytoma Invasion
Cancer Res., November 1, 2007; 67(21): 10241 - 10251.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S. Kumar Biswas, J. Huang, S. Persaud, and A. Basu
Down-regulation of Bcl-2 is associated with cisplatin resistance in human small cell lung cancer H69 cells
Mol. Cancer Ther., March 1, 2004; 3(3): 327 - 334.
[Abstract] [Full Text]


Home page
Cancer Res.Home page
A. S. Clark, K. A. West, P. M. Blumberg, and P. A. Dennis
Altered Protein Kinase C (PKC) Isoforms in Non-Small Cell Lung Cancer Cells: PKC{delta} Promotes Cellular Survival and Chemotherapeutic Resistance
Cancer Res., February 15, 2003; 63(4): 780 - 786.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
L. Ding, H. Wang, W. Lang, and L. Xiao
Protein Kinase C-{varepsilon} Promotes Survival of Lung Cancer Cells by Suppressing Apoptosis through Dysregulation of the Mitochondrial Caspase Pathway
J. Biol. Chem., September 20, 2002; 277(38): 35305 - 35313.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
C. L. Johnson, D. Lu, J. Huang, and A. Basu
Regulation of p53 Stabilization by DNA Damage and Protein Kinase C
Mol. Cancer Ther., August 1, 2002; 1(10): 861 - 867.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
D. MECHTCHERIAKOVA, G. SCHABBAUER, M. LUCERNA, M. CLAUSS, R. DE MARTIN, B. R. BINDER, and E. HOFER
Specificity, diversity, and convergence in VEGF and TNF-{alpha} signaling events leading to tissue factor up-regulation via EGR-1 in endothelial cells
FASEB J, January 1, 2001; 15(1): 230 - 242.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. Paolucci and E. Rozengurt
Protein Kinase D in Small Cell Lung Cancer Cells: Rapid Activation through Protein Kinase C
Cancer Res., February 1, 1999; 59(3): 572 - 577.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
A. Basu
The Involvement of Novel Protein Kinase C Isozymes in Influencing Sensitivity of Breast Cancer MCF-7 Cells to Tumor Necrosis Factor-{alpha}
Mol. Pharmacol., January 1, 1998; 53(1): 105 - 111.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 1996 by the American Association of Cancer Research.